Disease-Specific Websites by the Lymphoma Research Foundation

Despite the reality that there are so many subtypes of lymphoma, it is sometimes easy to forget that they are all entirely separate diseases. Saying that two people who have non-Hodgkin's lymphoma have the same disease is akin to saying that two people with heart disease suffer from the same disease: sure, it affects the same general part of the body but just about everything else is going to be drastically different.

This is highlighted by the Lymphoma Research Foundation's six different websites that address six different lymphoma diagnoses.

Follicular Lymphoma

This is the second most-commonly diagnosed subtype of NHL, accouting for roughly one quarter of all annual NHL diagnoses. Generally regarded as treatable but not curable, follicular lymphoma itself does not refer to one disease, but several. Check out focusonfl.org for more from the LRF.

Mantle Cell Lymphoma

Accounting for about six percent of NHL diagnoses annually, mantle cell lymphoma is a disease under almost constant revision, as researchers and heath care professionals learn more and more each day about this difficult subtype. Check out focusonmcl.org for more from the LRF on this disease.

Hodgkin's Lymphoma

More research ink has been spilled in the investigation of Hodgkin's than any other cancer, and stunning treatment success rates stand by as its glowing endorsement. Still, about one thousand people still die of this disease each year. Check out focusonhl.org for more from the LRF on this disease.

Chronic Lymphocytic Leukemia

CLL newly affects as many as 15,000 people each year, meaning that at least that many people will not only learn they have this disease each year but will also learn how confusing a clusterf**k is the naming system in lymphoma. This often-slow growing disease (chronic) has many treatment options. Check out focusoncll.org for more from the LRF on this disease.

Peripheral T-Cell Lymphoma

Of course if you think CLL is bad in the name game, you ain't seen nothing yet. Peripheral T-Cell Lymphoma isn't actually a disease, it's a category name for lymphomas affecting the T-cells. Technically you can't simply have PTCL; the diagnosis must be specified into something more confusing like adult T-cell leukemia/lymphoma. The most frequently diagnosed type of PTCL is, believe it or not, PTCL-NOS, 'not otherwise specified' (or 'we're not really sure'). Check out focusonptcl.org for more from the LRF on this disease.

Anaplastic Large Cell Lymphoma

The last of the LRF's disease-specific websites is devoted to anaplastic large cell lymphoma, representing about three percent of all NHL diagnoses. ALCL is a subtype of PTCL, meaning it affects the T-cells. It has a handful of its own subtypes, and is more commonly diagnosed in children. Check out focusonalcl.org for more from the LRF on this disease.

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap